British anti-Lewisite (BAL) reduces the severity of systemic and local responses of the eye after exposure to the chemical warfare agent surrogate for Lewisite, phenylarsine oxide (PAO)

英国抗路易氏剂 (BAL) 可减轻接触路易氏剂替代物苯胂氧化物 (PAO) 后眼睛的全身和局部反应的严重程度。

阅读:3

Abstract

Arsenical ocular toxicity is acute, painful, and aggressive. Although British anti-Lewisite (BAL) is an approved therapy for systemic arsenical toxicity, remedial measure for ocular exposure of arsenicals is still an unmet need. This study evaluated the efficacy of BAL as topical drop for ameliorating the pathogenesis incited by phenylarsine oxide (PAO, surrogate for lewisite), a chemical warfare agent. The binding of BAL to arsenic and calcium and zinc, two essential cellular minerals was determined using Isothermal Titration Calorimetry (ITC). Ex vivo, mouse corneas were tested with various concentrations of BAL (0.1 %, 1 %, and 5 %). Injury was induced ex vivo using PAO, 25 µg/5 µL, and rescue was evaluated with 1 % BAL. In-vivo, injury to mouse cornea was induced with PAO 100 µg/5 µL and rescue was evaluated by 1 % BAL. All eyes were assessed for physical symptoms by examination under slit lamp biomicroscope, anterior segment optical coherence tomography (AS-OCT), corneal thickness, and histopathological changes. BAL bonded strongly with arsenic but negligibly with calcium and zinc. Ex-vivo cornea, response with 1 % BAL was graded superior to higher concentration. One of eight mice with PAO injury survived versus all survivals in the PAO+BAL group after injury. Topical use of BAL mitigated the exacerbated ocular response exhibited by PAO injury. Histology revealed better preservation of retinal architecture in BAL treated mice. 1 % BAL alleviates PAO induced fatality in mice. The rescue in the posterior segment pathogenesis was remarkable. BAL is a promising decontaminant for ocular arsenical exposure and warrants further investigation.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。